CytoGenix Scientists Discover Bacterial Gene Silencing Therapeutic Technology - File for U.S. Patent.Business Editors/Health/Medical Writers HOUSTON--(BUSINESS WIRE)--Dec. 29, 2003 CytoGenix Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CYGX) CytoGenix announced Monday the filing of a United States Patent application entitled, "Oligodeoxynucleotide (ODN ODN Oligodeoxynucleotide ODN Optical Distribution Network ODN Optical Data Network ODN Ordnance Datum Newlyn (UK mapping coordinate system) ODN Online Dictionary of Neuroscience ODN Olathe Daily News ) Library, Their Use in Screening for Antibacterial Agents, and Catalytic ODN Sequence for Use as an Antibacterial Agent." This gene silencing technology is very different from presently used antibiotic agents. Now, scientists can identify and target genes that can kill pathogenic bacteria Pathogenic bacteria Bacteria that produce illness. Mentioned in: Gastroenteritis , stop their reproduction or prevent expression of their toxins. "The rapid emergence of antibiotic-resistant strains of pathogens has created an urgent demand for the discovery and development of antibacterial agents directed toward new targets. We have developed a novel method of identifying and blocking the expression of essential genes in bacterial cells, showing potential for developing highly specific and efficacious antibacterial agents. We believe that antibacterial agents developed with this new technology will be very safe and effective especially in hard to treat conditions such as sepsis, staph staph n. Staphylococcus. staph adj. and strep strep adj. Streptococcal. n. Streptococcus. infections," states Dr. Yin Chen, CytoGenix' vice president of Research and Development. Dr. Malcolm Skolnick, CytoGenix president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , adds, "This new technology can be used against many dangerous bacteria including potential bioterror pathogens. We are making this technology readily available for this purpose and we will share it with others and encourage anti-bioterror researchers to contact us about using this invention." CytoGenix Inc. is a biopharmaceutical company that develops and markets innovative products and services based on its proprietary DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. expression technology. CytoGenix has products in pre-clinical development including, anti-herpes, anti-psoriasis and anti-inflammatory topical creams. The company owns a U.S. patent for its core DNA expression technology and has 40 international or U.S. pending patent applications. SAFE HARBOR Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. : Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the Web site at www.cytogenix.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion